US 12,304,959 B2
Method of treating asthma with anti-IL1RAP antibodies
Davide Foletti, Menlo Park, CA (US); Erik Karrer, Los Altos, CA (US); Germaine Fuh-Kelly, Pacifica, CA (US); Kristie Ibarra, San Jose, CA (US); Quan Zheng, Fremont, CA (US); Yao-ming Huang, San Mateo, CA (US); Lindsay Deis, San Bruno, CA (US); Christine Wolak, Burlingame, CA (US); and Dominic Samuel Berns, Redwood City, CA (US)
Assigned to 23andMe, Inc., Sunnyvale, CA (US)
Filed by 23andMe, Inc., Sunnyvale, CA (US)
Filed on Sep. 27, 2021, as Appl. No. 17/486,864.
Application 17/486,864 is a division of application No. 16/541,990, filed on Aug. 15, 2019, granted, now 11,168,140.
Claims priority of provisional application 62/719,397, filed on Aug. 17, 2018.
Prior Publication US 2022/0106395 A1, Apr. 7, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); C12N 5/16 (2006.01)
CPC C07K 16/2866 (2013.01) [C12N 5/16 (2013.01); A61K 2039/505 (2013.01); C07K 2317/30 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01); C07K 2317/71 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01)] 19 Claims
 
1. A method of treating an IL1RAP mediated disease in a subject, wherein the IL1RAP mediated disease is asthma, comprising administering to the subject a therapeutically effective amount of an antibody, wherein the antibody comprises: (i) a first light chain hypervariable region (HVR-L1), a second light chain hypervariable region (HVR-L2), and a third light chain hypervariable region (HVR-L3), and (ii) a first heavy chain hypervariable region (HVR-H1), a second heavy chain hypervariable region (HVR-H2), and a third heavy chain hypervariable region (HVR-H3); wherein:
(a) HVR-L1 comprises an amino acid sequence of SEQ ID NO: 11;
(b) HVR-L2 comprises an amino acid sequence selected from SEQ ID NO: 37, and 54;
(c) HVR-L3 comprises an amino acid sequence selected from SEQ ID NO: 63, 69, and 70;
(d) HVR-H1 comprises an amino acid sequence of SEQ ID NO: 78;
(e) HVR-H2 comprises an amino acid sequence selected from SEQ ID NO: 191, and 195;
(f) HVR-H3 comprises an amino acid sequence selected from SEQ ID NO: 203 and 215.